335results about How to "Reduce pathogenicity" patented technology

A combination therapy comprising a therapeutically-effective amount of an epoxy-steroidal aldosterone receptor antagonist and a therapeutically-effective amount of a calcium channel blocker is described for treatment of circulatory disorders, including cardiovascular disorders such as hypertension, congestive heart failure, cirrhosis and ascites. Preferred calcium channel blockers are those compounds having high potency and bioavailability. Preferred epoxy-steroidal aldosterone receptor antagonists are 20-spiroxane steroidal compounds characterized by the presence of a 9alpha,11alpha-substituted epoxy moiety. A preferred combination therapy includes the calcium channel blocker verapamil HCl (Benzenacetonitrile, (±)-alpha[3[[2-(3,4-dimethoxyphenyl) ethyl]methylamino]propyl]-3,4-dimethoxy-alpha-(1-methylethyl)hydrochloride) and the aldosterone receptor antagonist epoxymexrenone.

Compounds having unique antiviral properties found in mushroom mycelium and their analogs are extracted, concentrated, isolated or manufactured to create compositions useful in preventing the spread and proliferation of various viruses afflicting animals, particularly viruses harming humans, pigs, birds, bats and bees. Such compounds and compositions can be used individually or in combination with known medicines or natural products to improve health.

The invention discloses a genotype VII Newcastle disease virus marker vaccine strain and an application thereof, and belongs to the field of genotype VII Newcastle disease virus marker vaccine strain rescue and application. A built Newcastle disease virus reverse genetic operating platform is utilized for enabling NP protein of a G7 strain to miss 18 amino acids and conducting mutation on F-protein cleavage loci, and the highly-weak virulence and high-virus titer genotype VII Newcastle disease virus marker vaccine strain MG7-NPdelta18+Fmut is rescued through screening. The microbial preservation serial number is CCTCC NO: V201505. The marker vaccine strain has the biological characteristics of high growth titer and low virulence in chick embryos and is genetically stable. The immune protection test result shows that the marker vaccine strain is good in immunogenicity, capable of inducing high-level protective antibodies, and capable of completely protecting immunized chicken, can be used for preventing and controlling a currently-popular genotype VII Newcastle disease virus and lays the foundation of identifying vaccine immunity and wild virus infection.

The present invention provides three insertion elements and transposases encoded by the insertion elements that are derived from the genome of Ralstonia solanacearum, which has been isolated with a transposon trap vector.

Live, attenuated recombinant rabies virus vaccines are generated using reverse genetics to combine the antigenic determinants that render the rabies virus non-pathogenic with the determinants that are responsible for the elicitation of an effective anti-rabies immune response. These vaccines do not affect the antigenic, and therefore the immunogenic, properties of the virus. The present invention further relates to recombinant rabies virus vaccines that express a pro-apoptotic protein, such as cytochrome c, to increase the capacity to induce apoptosis, thereby enhancing the protective immunity against rabies. This new generation of live rabies virus vaccines represents a safe and effective approach to the eradication of rabies in wildlife, and subsequently humans and livestock.

The invention discloses a pathogenic related protein VdGRP1 from verticillium dahliae kleb and a coded gene thereof. The pathogenic related protein is the protein of 1) or 2): 1) the protein consisting of the amino acid sequence shown as sequence 2 in a sequence table; and 2) the protein formed by substituting and/or deleting and/or adding one or more amino acid residues of the amino acid residuesequence shown as sequence 2 in the sequence table, related to pathogenic fungi and derived from 1). A mutant strain vdgrpl of which the pathogenicity is weakened is obtained by screening a verticillium dahliae kleb mutant library mediated by agrobacterium tumefaciens and built through T-DNA insertion technology by the inventor. Southern hybridization proves that the mutant strain is a T-DNA single-insertion mutant. A gene causing mutant phenotype is obtained through TAIL-PCR technology by the inventor. Gene complementation tests prove that the mutation of the gene VdGRP1 weakens the pathogenicity of the strain vdgrpl which means that the gene VdGRP1 is a fungi pathogenic related gene.

The invention belongs to the technical field of biology, and particularly relates to an African swine fever virus attenuated strain lacking an MGF360-9L gene and an application of the African swine fever virus attenuated strain. The MGF360-9L gene of the African classical swine fever virus has a function of obviously inhibiting the response of a host face, and according to the African swine fevervirus attenuated strain lacking the MGF360-9L gene, the gene MGF-360-9L is knocked out from the whole genome of an ASFV CN/GS/2018 isolated strain by adopting a genetic engineering means and utilizinga homologous recombination method, so that the aim of reducing the virulence is achieved. Experimental results of target animal piglets show that the African swine fever virus attenuated strain lacking the MGF360-9L single gene has good use safety and can be used as a candidate strain for preparing African swine fever vaccines.

A novel pharmaceutical composition is provided by which nonsteroidal anti-inflammatory drugs (NSAIDs) are added directly to phospholipid-containing oil such as lecithin oils or to a bio-compatible oil to which an phospholipid has been added to make a NSAID-containing formulation that possess low gastrointestinal (GI) toxicity and enhanced therapeutic activity to treat or prevent inflammation, pain, fever, platelet aggregation, tissue ulcerations and/or other tissue disorders. The composition of the invention are in the form of a non-aqueous solution, paste, suspension, dispersion, colloidal suspension or in the form of an aqueous emulsion or microemulsion for internal, oral, direct or topical administration.

The present invention provides purified protease inhibitors derived from microorganisms alone or in combination with bacteriocins and/or antibodies. The protease inhibitors may also be expressed by microbiome or probiotic microorganisms alone or in combination with bacteriocins and/or antibodies. The invention also provides methods and compositions for improving the expression of endogenous or heterologous protease inhibitors alone or in combination with bacteriocins and/or antibodies. The invention is useful for treating a variety of inflammatory disorders including acne, psoriasis, eczema, atopic dermatitis and inflammatory bowel disease.

The invention provides building and application of an M protein three-amino acid site-mutated vesicular stomatitis virus (VSV) carrier for pigs. The VSV carrier is matrix protein (M) three-amino acid site-mutated recombinant virus VSV-MT, the 51st-site methionine of the virus M protein is knocked out, the 221st-site valine of the virus M protein is mutated into phenylalanine, and the 226th-site glycine of the virus M protein is mutated into arginine. The VSV carrier is extremely low in pathogenicity, high in safety, capable of effectively stimulate a body to produce protective immune response, applicable to vaccine or vaccine carrier preparation, and promising in application prospect.

The invention relates to a VII type Newcastle disease virus L-gene mutation attenuated vaccine strain produced by using a reverse genetic manipulation technology and a preparation method of the VII type Newcastle disease virus L-gene mutation attenuated vaccine strain, and belongs to the field of biological products and biological technologies. Toxicity of the VII type Newcastle disease virus L-gene mutation attenuated vaccine strain is weakened obviously, and at the same time, the vaccine strain on a chick embryo has high titer, stable heritability and high compatibility to an antigen of a prevalent virus, is suitable for large-scale production of vaccines, and can be used for producing the vaccines. Compared with conventional vaccines (gene I and gene II types), the VII type Newcastle disease virus L-gene mutation attenuated vaccine strain has a wide application prospect in control of incidence and prevalence of the Newcastle diseases.

The invention relates to a Newcastle disease chimeric virus marker vaccine strain as well as a construction method and application thereof, and belongs to the field of rescue and application of Newcastle disease chimeric vaccine strains. A Newcastle disease virus reverse genetic operation platform is utilized to mutate an F protein cleavage site of a Newcastle disease gene GVII type strain into acleavage site of an attenuated strain, F and HN genes of a mutated gene VII type Newcastle disease strain and NP, P, M and L of a gene II type NDV La Sota strain construct a full-length chimeric cDNAsequence, and a 18bp nucleotide marker sequence is inserted into a non-coding region between P and M. A Newcastle disease chimeric virus NDV DC strain is obtained through transfection cell rescue. Theconstructed chimeric virus can reach relatively high culture titer in chick embryos and cells. The chimeric strain contains envelope surface glycoprotein of the gene VII type Newcastle disease strain, contains a skeleton of the gene II type strain, and has immunogenicity of the Newcastle disease gene VII type strain and high reproduction and high safety characteristics of the gene II type La Sotastrain.

The present invention discloses a method for attaining potato plates which are disease resistant by utilizing agrobacterium-mediated hrap gene. After the combined inoculation of the method and the bacteria allergic protein harpinPss, the allergic reaction caused by harpinPss can be promoted in the intercellular space of all inoculated plates, and the polymeride of harpinPss is dissociated, so the disease resisting effect is better, and the disease resistance of the potato plates can be promoted. The hrap gene is introduced in the potato plates through the agrobacterium-mediated, thus resulting that the potato plates have the ability to resist the late blight and the bacterial wilt. The present invention has the technical proposal that the pre-cultured explants are inoculated in the agrobacterium germ liquid to be soaked, explants after being soaked select the tube seedling which can root after two times of root selections by co-culturing, callus of induce, bud inducting and rootage cultivating and selecting, and the potted transformed plants are transferred after the mass propagation, the transformed plants select positive plants by the methods of the PCR detection and the Southern hybridization detection, and then the potato plates which are disease resistant can be obtained by the in-vivo inoculation resistance identification. The present invention improves the callus of inducing and the bud inducing of the explants, and enhances the agrobacterium-mediated ability. That the roots of the explants are selected by two times can eliminate the false positive plates in the transformation process , avoid the continuing cultivation to the false positive plates, save the labour force and decrease the manufacturing cost.

The invention is suitable for the field of nematode disease control and provides a method for controlling pine wood nematode diseases by utilizing body surface bacteria of American pine wood nematodes. The method comprises the steps of: spraying American bacterium suspension liquid into woodlands: spraying once in May for two years in a row, wherein the body surface pathogenic bacteria of the pine wood nematodes are replaced with American bacteria in two or three years so as to control the prevalence of woodland pine wood nematode diseases in China. According to the invention, the biological control is carried out by utilizing the replacement of ecological niche of the body surface bacteria of the pine wood nematodes and bacterial strains isolated and screened from body walls of the American pine wood nematodes. In the method, the biocontrol bacteria sprayed into the woodlands have the characteristics of low pathogenicity, strong reproduction and replacement capabilities and the like and are capable of rapidly replacing the body surface strong pathogenic bacteria of the pine wood nematodes in China to ensure that the pine wood nematodes lose the pathogenic ability and the purpose of controlling the prevalence of pine wood nematode diseases is achieved. The method has the advantages of simpleness, practicability, easiness in popularization and application, lower cost, good and thorough effect and the like.

The invention discloses a VdUDG gene and an application thereof in reducing the pathogenicity of verticillium dahliae. The protein disclosed by the invention is (1) protein shown by SEQ ID No.15; or (2) protein obtained by substituting and/or losing and/or adding one or multiple amino acid residues of the amino acid sequence shown by SEQ ID No.15 and having the same function. The invention proves that the VdUDG gene is an essential factor during the formation of microsclerotia and plays an important role in the processes of verticillium dahliae pathopoiesia, microsclerotia formation and spore production. The invention promotes study on the pathogenesis of cotton verticillium dahliae and finally provides a theoretical basis to developing a new strategy of preventing and controlling verticillium wilt.

The present invention provides cell fusogenic vectors having replicative ability, whose protease-dependent tropism has been modified. M gene-deficient viral vectors encoding modified F proteins, in which the cleavage site of the F protein of paramyxovirus is modified to be cleaved by different proteases, were produced. In cells transfected with these vectors, the genomic RNA present in the vectors is replicated, and cell fusogenic infection spreads to neighboring cells depending on the presence of other proteases; however, no viral particles are released. The vectors of this invention, encoding the F proteins which are cleaved by proteases whose activity is enhanced in cancer, show cancer growth suppressive effect in vivo.

The invention relates to compositions and methods for treating inflammatory diseases and disorders in a subject in need thereof. In certain aspects, the invention relates to immunogenic compositions (e.g., vaccines) to diminish the number or pathogenic effects of one or more bacteria associated with the development or progression of an inflammatory disease or disorder.

The present invention is a culture of cells of Haemophilus parasuis exhibiting attenuated pathogenicity and capable of triggering a protective immune response when administered to pigs as a live vaccine. The present invention is also a method of preparing the cell culture, a method of preparing a vaccine from the cell culture, and a live vaccine based on the cell culture. The cell culture was modified from a pathogenic parent strain by MNNG mutagenesis and was selected by complete dependence on streptomycin for growth.

The invention relates to a recombination newcastle disease LaSota attenuated vaccine for expressing canine distemper virus fusion protein (F) or canine distemper virus hemagglutinin protein (H). Particularly, the recombination newcastle disease LaSota attenuated vaccine is rLa-CDVR-F or rLa-CDVR-H. The invention further discloses a method for preparing the recombination newcastle disease LaSota attenuated vaccine and application of the recombination newcastle disease LaSota attenuated vaccine in preparation of vaccines/kits.

The invention discloses a method for constructing genetic engineering strains for producing (R)-acetoin and application of the genetic engineering strains. The method includes optimizing codons of nucleotide sequences of alpha-acetolactate synthase genes, alpha-acetolactate decarboxylase genes and NADH (reduced form of nicotinamide adenine dinucleotide) oxidase genes and acquiring each gene cluster with three genes by the aid of artificial synthesis processes; inserting the gene clusters into expression vectors to obtain polycistron recombinant plasmids; introducing the polycistron recombinant plasmids into host bacteria E. coli and knocking out key genes of main byproduct synthesis paths to obtain the genetic engineering strains for producing the (R)-acetoin. The method and the application have the advantages that raw materials for the genetic engineering strains can come from wide sources and are low in cost, the strains are free of pathogenicity, oxidized form coenzymes NAD+ (nicotinamide adenine dinucleotide+) can be effectively regenerated, the strains are high in (R)-acetoin yield and production efficiency, the maximum yield can reach 72.1 g/L, and the optical purity can reach 99% at least; the (R)-acetoin is produced by the aid of non-grain cassava flour and inexpensive nitrogen sources which are used as fermentation raw materials, and accordingly the production cost can be reduced.

The invention relates to an avian infectious bronchitis virus attenuated virus strain rH120-YZ and a construction method thereof. The microbial preservation number of the avian infectious bronchitis virus attenuated virus strain rH120-YZ is CGMCCNo. 8501. The invention relates to an application of a reverse genetic manipulation technology. By using a constructed reverse genetic manipulation platform of the avian infectious bronchitis virus attenuated virus strain rH120-YZ and adopting a spike protein gene S of an avian infectious bronchitis virus attenuated virus isolate ck/CH/IBYZ/2011 to replace a corresponding part of the H120 vaccine strain genome, a recombinant virus rH120-YZ is saved and obtained. The virus has relatively low pathogenicity on chicks, has a relatively high breeding titer on chick embryos, is suitable for large-scaled production of infectious bronchitis vaccines and can be used for manufacturing vaccines.